What We're Reading: Page 394
Industry reads hand-picked by our editors
Mar 09, 2015
-
Bloomberg
Wall Street shrugging off high costs of new cancer treatments
-
The Telegraph
What's in store for Glaxo's new chairman?
-
In-Pharmatechnologist
Hospira's recall woes not over yet
-
Contract Pharma
Isis Pharma bags Biogen milestone
-
Indianapolis Business Journal
Lilly hopes NASCAR driver sponsorship will boost diabetes sales
Mar 06, 2015
-
FDA
FDA launches first drug-shortages mobile app
-
AbbVie beats out J&J, will buy Pharmacyclics for $21B to boost cancer pipeline
-
-
-
AstraZeneca to spin off antibiotics R&D for $40 million
-
BMS' Opdivo wins lung cancer indication more than 3 months before PDUFA date
-
Genentech denies knowledge of distribution-related problems
-
-
-
Akorn latest to reject use of its drugs for lethal injection
Mar 05, 2015
-
Could Sangamo's gene therapy 'cure' HIV?
-
-
-
The post-acquisition cuts begin: Valeant lays off 77 Dendreon employees
-
-
SEC to pharma: Don't get cute with disclosing FDA dealings to investors
-
-
BI files its Pradaxa 'antidote' in North America, EU
-
FDA clamps down on testosterone labeling rules
-
Orexigen shoots itself in foot with early disclosure of positive Contrave heart data
Mar 04, 2015
-
AZ board to CEO Soriot: Want that big bonus? Show us the money
-
-
-
Celgene's Abraxane approved in EU for first-line treatement of NSCLC
-
US lawmakers push Amphastar for answers on naloxone prices
-
-
-
Survey: New Genentech distribution policy delaying cancer patients' care
-
-
Gilead seals generic Sovaldi deal with Natco, NICE rec for Harvoni in UK
Mar 03, 2015
-
-
-
-
BMS' Opdivo wins lung cancer indication more than 3 months before PDUFA date
-
Ousted Sanofi chief Chris Viebacher lands at PureTech
-
How 23andMe used rigorous clinical trials to win a landmark FDA authorization
-
A biotech is bringing a new IUD to market—but the company's a nonprofit
-
-
-
Indian advisory board proposes waiving phase III for certain drugs
Mar 02, 2015
-
Positive phase II Provenge data a good early sign for ambitious Valeant
-
-
-
-
EU approves first new chemical entity for Parkinson's in a decade
-
-
A booming Bayer projects 10% pharma-driven growth in 2015
-
Gilead raking in billions off of foreign tax laws
-
GSK's CEO faces another pay cut—and it's a big one
-
Feb 27, 2015
-
-
-
UPDATE: Sanofi's likely blockbuster insulin Toujeo wins FDA approval
-
Federal judge strikes down Maine's controversial prescription drug import law
-
-
Game time: Remicade biosims from Celltrion, Hospira launch in big EU markets
-
-
CA lawmaker to pharma: Show us, with numbers, why drugs cost so much
-
Pharmacyclics surges on news of potential sale to J&J, Novartis
-
FDA approves Actavis' QIDP-designated antibiotic combo
Previous
